Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA and MINOCA-mimics
Launched by UNIVERSITY OF ZURICH · Mar 14, 2024
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying patients who have experienced a type of heart attack called acute myocardial infarction but do not have significant blockages in their coronary arteries, known as MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries). The researchers want to learn more about how well the small blood vessels in the heart are working and how this might affect a person's recovery and future heart health. They will use a special imaging technique called advanced cardiac magnetic resonance (CMR) to take detailed pictures of the heart within 10 days of the heart event and again three months later.
To participate, individuals should be experiencing symptoms of a heart attack or myocarditis (inflammation of the heart) and have elevated heart-related markers in their blood, but no significant blockages found during imaging tests. The trial is open to adults aged 65 to 74, regardless of gender. Participants will undergo advanced imaging to help researchers better understand heart function and identify any potential risks for future heart problems. If you have certain medical conditions or devices, such as a pacemaker, you may not be eligible. This research aims to improve the care and outcomes for patients with similar heart conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • acute presentation with signs/symptoms of acute coronary syndrome or myocarditis
- • elevated cardiac biomarkers
- • no signficant coronary artery disease on coronary angiogram or coronary CT
- Exclusion Criteria:
- • pacemaker/other devices or claustrophobia
- • severe asthma, chronic obstructive lung or kidney disease
- • acute pulmonary embolism
- • arrhythmia on ECG
- • moderate to severe valvular disease
About University Of Zurich
The University of Zurich, a leading institution in research and education, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust framework for conducting high-quality research, the university collaborates with multidisciplinary teams of experts to explore cutting-edge therapeutic approaches and interventions. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the utmost integrity, aiming to contribute valuable insights to the medical community and enhance health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zürich, , Switzerland
Patients applied
Trial Officials
Robert Manka, Prof. MD
Principal Investigator
University of Zurich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported